ArticleCancer immunology, immunotherapy : CII2022

Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma.

Wataru Fukuokaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.